Compare AXTA & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXTA | BLTE |
|---|---|---|
| Founded | 1910 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paints/Coatings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.0B |
| IPO Year | 2014 | 2021 |
| Metric | AXTA | BLTE |
|---|---|---|
| Price | $34.39 | $143.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 9 |
| Target Price | $39.00 | ★ $228.89 |
| AVG Volume (30 Days) | ★ 1.6M | 128.3K |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $5,117,000,000.00 | N/A |
| Revenue This Year | $2.37 | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | $81.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.94 | $91.40 |
| 52 Week High | $38.61 | $200.00 |
| Indicator | AXTA | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 35.98 |
| Support Level | $33.24 | $132.50 |
| Resistance Level | $35.48 | $161.08 |
| Average True Range (ATR) | 0.71 | 5.99 |
| MACD | 0.23 | -0.62 |
| Stochastic Oscillator | 67.82 | 6.50 |
Axalta Coating Systems Ltd is a manufacturer, marketer, and distributor of high-performance coatings systems. It operates in two segments: Performance Coatings and Mobility Coatings. The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial, and the Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The majority of its revenue is generated from the Mobility Coatings segment. Geographically, the company generates maximum revenue from the Europe, Middle East and Africa (EMEA) region, followed by North America, Asia Pacific, and Latin America.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.